Karim Rihawi
Azienda USL di Bologna(IT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies(2020)171 cited
- → Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications(2021)166 cited
- → Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?(2021)96 cited
- → Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management(2016)62 cited
- → Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?(2015)55 cited
- → Ramucirumab: preclinical research and clinical development(2014)53 cited
- → MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report(2018)45 cited
- → Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours(2020)41 cited
- → BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience(2019)41 cited
- → A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification(2017)39 cited